146 related articles for article (PubMed ID: 9988223)
1. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
Braun S; Hepp F; Sommer HL; Pantel K
Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
3. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
[TBL] [Abstract][Full Text] [Related]
4. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
5. Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
Kasimir-Bauer S; Otterbach F; Oberhoff C; Schmid KW; Kimmig R; Seeber S
Int J Mol Med; 2003 Dec; 12(6):969-75. PubMed ID: 14612976
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
[TBL] [Abstract][Full Text] [Related]
7. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells.
Kirchner EM; Gerhards R; Voigtmann R
Ann Oncol; 2002 Jul; 13(7):1044-8. PubMed ID: 12176782
[TBL] [Abstract][Full Text] [Related]
8. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.
Pantel K; Schlimok G; Angstwurm M; Weckermann D; Schmaus W; Gath H; Passlick B; Izbicki JR; Riethmüller G
J Hematother; 1994; 3(3):165-73. PubMed ID: 7530132
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.
Pantel K; Schlimok G; Braun S; Kutter D; Lindemann F; Schaller G; Funke I; Izbicki JR; Riethmüller G
J Natl Cancer Inst; 1993 Sep; 85(17):1419-24. PubMed ID: 7688814
[TBL] [Abstract][Full Text] [Related]
10. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.
Schlimok G; Funke I; Holzmann B; Göttlinger G; Schmidt G; Häuser H; Swierkot S; Warnecke HH; Schneider B; Koprowski H; Riethmüller G
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8672-6. PubMed ID: 2446326
[TBL] [Abstract][Full Text] [Related]
11. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
[TBL] [Abstract][Full Text] [Related]
14. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.
Janni W; Gastroph S; Hepp F; Kentenich C; Rjosk D; Schindlbeck C; Dimpfl T; Sommer H; Braun S
Cancer; 2000 May; 88(10):2252-9. PubMed ID: 10820346
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Becker S; Pergola-Becker G; Bachmann R; Krämer B; Vogel U; Neubauer H; Wallwiener D; Huober J; Fehm TN
Breast Cancer Res Treat; 2006 Jul; 98(2):179-84. PubMed ID: 16552629
[TBL] [Abstract][Full Text] [Related]
17. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
[TBL] [Abstract][Full Text] [Related]
18. Rating of isolated disseminated tumor cells in bone marrow in comparison with other factors of prognosis in breast carcinoma.
Leinung S; Würl P; Schönfelder A; Weiss CL; Röder I; Schönfelder M
Int J Surg Investig; 2000; 2(3):193-202. PubMed ID: 12678519
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?
Kasimir-Bauer S; Oberhoff C; Sliwinska K; Neumann R; Schindler AE; Seeber S
Breast Cancer Res Treat; 2001 Sep; 69(2):123-32. PubMed ID: 11759818
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.
Pierga JY; Deneux L; Bonneton C; Vincent-Salomon A; Nos C; Anract P; Magdelénat H; Pouillart P; Thiery JP
Int J Biol Markers; 2004; 19(1):23-31. PubMed ID: 15077923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
